Image Image Image Image Image Image Image Image Image Image
Accessibilité
Haut de page

Up

En quoi nous distinguons-nous des autres? 

Médecine 360º

À la rigueur médicale qui nous caractérise, viennent s’ajouter d’autres prestations pour une prise en charge globale du patient avec un programme de services exclusifs gratuits.

  • Prise en charge psychologique.
  • Conseil en nutrition.
  • Conseil dans les technologies d'assistance.
  • Service d'accompagnement.
Entre autres services. + Voir plus

Actualités + Voir plus

bengala
23/06/2022.
Pyrotechnics: caution, protection and distance
We at the Institut de la Màcula want to focus on the eye injuries tha...

Actualités

pentacam axl wave
09/05/2022.
The Institut de la Màcula incorporates state-of-the-art diagnostic equipment for corneal refractive surgery and premium cataract surgery
When approaching surgery, it is essential to have precise measurements...

Actualités

Young tired working woman at work
20/04/2022.
How to deal with allergic conjunctivitis
Allergic conjunctivitis usually presents in the spring, although it ca...

Actualités

Míriam Garcia i Marc Biarnés
24/03/2022.
Clues on the posterior segment for non-ophthalmologist healthcare professionals
Marc Biarnés and Míriam Garcia, opto...

Actualités

Recherche + Voir plus

OCT OI
25/09/2022.
MANTRA: evaluating the association between retinal sensitivity and retinal flow in AMD
Description

Multicenter prospective observational study to evaluate the association between retinal sensitivity and retinal flow in age-related macular degeneration (AMD).

Goal

The present study aims to evaluate the relationship between retinal sensitivity measured with MAIA Microperimetry and coexisting retinal fluid measured with OCT Spectralis in patients with macular degeneration candidates for anti-VEGF treatments according to clinical practice.

Inclusion criteria
  • Age ≥ 50 years.
  • Bilateral or unilateral AMD diagnosis.
  • Maximum corrected visual acuity ≥ 20/63.
  • Presence of predominantly active type I lesion.
  • Not having received any anti-VEGF treatment previously.
Duration

Patients will be followed for 18 months.

...

Recherche

velodrome
22/05/2022.
VELODROME: efficacy, safety and pharmacokinetics of ranibizumab 100 mg/ml through a PDS in patients with nDMAE
Description

This study will evaluate the efficacy, safety and pharmacokinetics of ranibizumab 100 mg/ml released through a port-delivery system (PDS) will refill each 6 weeks as compared with a refill each 24 months in patients with neovascular age-related macular degeneration (nAMD).

Aim

The main objective is to evaluate the efficacy of ranibizumab 100 mg/ml delivered through a PDS system with refills at week 36 as compared to that at week 24.

Inclusion criteria

Patients older than 50 years diagnosed with nAMD in the 9 months prior to the selection visit. These patients need to receive a minimum of 3 intravitreal injections in the prior 6 months with proven response to therapy. If this last criterion is not met, the patient may enter a run-in phase where she/he will receive the minimum number of injections to met these requirements.

Duration

Between 24 and 36 weeks.

...

Recherche Recrutement

talon
15/05/2022.
TALON (Extension): efficacy and safety of brolucizumab 6 mg in a maximum interval dosing schedule of 20 weeks for patients with nDMAE
Description

A phase IIIb/IV open-label extension study with a single arm of 56 weeks to evaluate the efficacy and safety of brolucizumab 6 mg in a maximum interval dosing schedule of 20 weeks for the treatment of patients with neovascular age-related macular degeneration (nAMD) that completed the CRTH258A2303 (TALON) study.

Aims
  • To evaluate the efficacy and safety of brolucizumab in patients with nAMD to evaluate the potential for achieving an interval of up to 20 weeks between intravitreal injections.
  • To evaluate the durability of brolucizumab up to the week 56.
  • To determine the functional effects of brolucizumab as measured on the change of best-corrected visual acuity between baseline and the mean of weeks 52 and 56.
Drug

Brolucizumab 6 mg/0,05 Ml.

Inclusion criteria

Participants who have successfully completed the TALON study up to week 64 (end of study visit).

Duration

56 weeks.

...

Recherche

AG RETINO OS
15/05/2022.
GALE: evaluating the long-term safety and efficacy of intravitreal pegcetacoplan in patients with GA secondary to AMD
Description

Its'a Phase III, open-label, multicenter clinical trial evaluating the long-term safety and efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Goal

The main objective of this study is to evaluate the long-term safety of intravitreal pegcetacoplan, as well as the changes in the lesion measured by autofluorescence.

Drug

Biochemical, genetic and clinical lines of evidence in humans indicate that the complement system plays a role in the aetiology of AMD. Complement protein C3 (which has a pro-inflammatory action), membrane attack complex and complement factor H are present in the drusen and basal laminar deposits of patients with AMD. Pegcetacoplan is a drug for intravitreal use that blocks the action of C3. The main action is anti-inflammatory.

Inclusion criteria

This study only accepts patients who have participated in the APL2-103 study or have completed the 24-month treatment of the APL2-303 (DERBY) or APL2-304 (OAKS) studies.

Duration

The duration of the trial is three years.

...

Recherche

Patients internationaux

Vous ne résidez pas à Barcelone et souhaitez vous faire soigner à l'Institut de la Màcula ? Cliquez ici . Vous trouverez toutes les informations dont vous avez besoin.

Aidez-nous à stopper les maladies dégénératives de l’œil. La BMF se consacre à la recherche de traitements capables d’inverser de plus en plus de formes de cécité. Collaborez avec la Barcelona Macula Foundation: Research for Vision

BMF-transp
Last modified: 4 December, 2022 - 19:33


Open chat